

Aaron T Gerds

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4034214/aaron-t-gerds-publications-by-citations.pdf>
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95 papers	1,290 citations	17 h-index	33 g-index
101 ext. papers	1,752 ext. citations	3.6 avg, IF	4.21 L-index

#	Paper	IF	Citations
95	Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1211-8	4.7	137
94	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 652-659	13.4	133
93	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015 , 125, 1857-65	2.2	118
92	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 89-97	4.7	99
91	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017 , 3, 1675-1682	13.4	78
90	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1831-1839	2.2	67
89	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1864-71	2.2	46
88	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017 , 179, 781-789	4.5	36
87	A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis. <i>Blood</i> , 2019 , 134, 556-556	2.2	31
86	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. <i>Blood Advances</i> , 2020 , 4, 4282-4291	7.8	29
85	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 767-775	4.7	27
84	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. <i>Blood Advances</i> , 2020 , 4, 5825-5835	7.8	26
83	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020 , 4, 1965-1973	7.8	23
82	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , 2018 , 8, 4	7	21
81	Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. <i>Blood Advances</i> , 2020 , 4, 5246-5256	7.8	21
80	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019 , 79, 38-44	2.7	20
79	Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e463-e468	2	18

78	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1281-1286	4.4	17
77	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016 , 128, 216-216	2.2	16
76	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019 , 3, 4228-4237	7.8	16
75	Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib. <i>Blood</i> , 2019 , 134, 667-667	2.2	14
74	Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1565-1575	4.7	12
73	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 971-979	4.7	11
72	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1029-1034	4.7	11
71	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1195-1201	1.9	10
70	Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count . <i>Blood</i> , 2019 , 134, 4175-4175	2.2	10
69	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020 , 105, e98-e101	6.6	10
68	Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes. <i>Leukemia and Lymphoma</i> , 2018 , 59, 803-812	1.9	10
67	Transplantation for myelodysplastic syndrome in the era of hypomethylating agents. <i>Current Opinion in Hematology</i> , 2012 , 19, 71-5	3.3	9
66	Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. <i>Blood Advances</i> , 2020 , 4, 5562-5573	7.8	9
65	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, E49-E52	7.1	9
64	Polycythemia Vera Management and Challenges in the Community Health Setting. <i>Oncology</i> , 2017 , 92, 179-189	3.6	8
63	Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1141-1144	4.7	8
62	Effect of bone marrow CD34+ cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 775-781	4.4	8
61	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 472-479	4.7	7

60	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019 , 3, 2732-2737	7.8	7
59	The association of histologic grade with acute graft-versus-host disease response and outcomes. <i>American Journal of Hematology</i> , 2017 , 92, 683-688	7.1	6
58	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 579-584.e1	2	6
57	Established and novel agents for myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 82-9	3.1	6
56	Rationale for and Results of a Phase I Study of the TGF- β /3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial. <i>Blood</i> , 2020 , 136, 6-8	2.2	6
55	The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. <i>Annals of Hematology</i> , 2020 , 99, 7-19	3	6
54	Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2021 ,	2.2	6
53	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1588-1595	4.7	6
52	I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 400-6	4.4	5
51	Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study. <i>Blood</i> , 2020 , 136, 29-31	2.2	5
50	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2020 , 13, 32-39	2.7	5
49	Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020 , 4, 4748-4757	7.8	5
48	Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 262-271	4.7	5
47	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 219-225	2	5
46	Albumin as a prognostic marker in myelodysplastic syndromes: still relevant after all these years. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2491-2	1.9	4
45	Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 582-591	4.4	4
44	Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2221-2	1.9	4
43	A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis. <i>Blood</i> , 2021 , 138, 139-139	2.2	4

42	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4
41	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2019 , 32, 104-113	4.2	3
40	Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015 , 52, 249-55	4	3
39	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. <i>Leukemia and Lymphoma</i> , 2018 , 59, 363-371	1.9	3
38	Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?. <i>Oncologist</i> , 2016 , 21, 475-80	5.7	3
37	Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 292-9	4.4	3
36	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. <i>Blood</i> , 2020 , 136, 33-34	2.2	3
35	Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations. <i>Blood</i> , 2015 , 126, 740-740	2.2	3
34	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1344-1352	1.9	3
33	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2811-2820	1.9	3
32	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020 , 13, 160-165	2.7	3
31	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e95-e102	2	3
30	Paradigm shift: combination BET and JAK inhibition in myelofibrosis. <i>Leukemia</i> , 2021 , 35, 3361-3363	10.7	3
29	Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 455-460	4.4	2
28	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. <i>Blood</i> , 2020 , 136, 38-39	2.2	2
27	Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.. <i>Blood Advances</i> , 2021 ,	7.8	2
26	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 4238-4238	2.2	2
25	A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes. <i>Blood</i> , 2020 , 136, 33-35	2.2	2

24	Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 407-414	3.1	2
23	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 735-738	1.9	2
22	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. <i>Blood Advances</i> , 2021 , 5, 4361-4369	7.8	2
21	Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e374-e376	2	1
20	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1943-1953	1.9	1
19	Darbepoetin alfa for anemia with myelodysplastic syndrome. <i>Expert Review of Hematology</i> , 2015 , 8, 139-146	4.6	1
18	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 13-14	2.2	1
17	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2696-2696	2.2	1
16	Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence. <i>Blood</i> , 2020 , 136, 31-32	2.2	1
15	Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression. <i>Blood</i> , 2014 , 124, 2642-2642	2.2	1
14	A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 715-716	4.7	0
13	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 2899-2899	2.2	0
12	Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.. <i>Oncologist</i> , 2022 , 27, 228-235	5.7	0
11	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 917.e1-917.e9		0
10	Momelotinib reduces transfusion requirements in patients with myelofibrosis.. <i>Leukemia and Lymphoma</i> , 2022 , 1-5	1.9	0
9	Time, timing, and the treatment of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 247-248	1.9	
8	Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic. <i>Blood</i> , 2020 , 136, 41-42	2.2	
7	To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 655-62	0.6	

- 6 Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis. *Blood*, **2021**, 138, 3638-3638 2.2
- 5 Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2021**, 4.4
- 4 Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2075-2075 2.2
- 3 A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. *Blood*, **2019**, 134, 2595-2595 2.3
- 2 Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). *Blood*, **2016**, 128, 4666-4666 2.2
- 1 Myelodysplastic/myeloproliferative neoplasm overlap syndromes 120-128